ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 88 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 1.26 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $21,483 | -24.2% | 65,900 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $28,337 | -53.9% | 65,900 | -43.1% | 0.00% | -50.0% |
Q4 2022 | $61,427 | -27.7% | 115,900 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $85,000 | -55.0% | 115,900 | -30.1% | 0.00% | -50.0% |
Q2 2022 | $189,000 | -47.6% | 165,900 | -5.7% | 0.00% | -42.9% |
Q1 2022 | $361,000 | -36.6% | 175,900 | -11.0% | 0.01% | -36.4% |
Q4 2021 | $569,000 | -45.8% | 197,600 | -20.2% | 0.01% | -45.0% |
Q3 2021 | $1,050,000 | +32.7% | 247,600 | +65.5% | 0.02% | +42.9% |
Q2 2021 | $791,000 | +23.8% | 149,600 | +8.9% | 0.01% | +16.7% |
Q1 2021 | $639,000 | +41.1% | 137,400 | 0.0% | 0.01% | +20.0% |
Q4 2020 | $453,000 | +32.8% | 137,400 | +33.5% | 0.01% | +25.0% |
Q3 2020 | $341,000 | -15.2% | 102,900 | -13.7% | 0.01% | 0.0% |
Q2 2020 | $402,000 | +140.7% | 119,200 | +172.8% | 0.01% | +100.0% |
Q1 2020 | $167,000 | -70.5% | 43,700 | -53.4% | 0.00% | -50.0% |
Q4 2019 | $566,000 | -7.1% | 93,700 | +16.4% | 0.01% | 0.0% |
Q3 2019 | $609,000 | -44.2% | 80,500 | 0.0% | 0.01% | -42.9% |
Q2 2019 | $1,091,000 | +150.2% | 80,500 | 0.0% | 0.01% | +180.0% |
Q1 2019 | $436,000 | +164.2% | 80,500 | +45.0% | 0.01% | +150.0% |
Q4 2018 | $165,000 | -63.6% | 55,500 | 0.0% | 0.00% | -50.0% |
Q3 2018 | $453,000 | -16.3% | 55,500 | 0.0% | 0.00% | -20.0% |
Q2 2018 | $541,000 | +27.0% | 55,500 | +13.3% | 0.01% | 0.0% |
Q1 2018 | $426,000 | -30.5% | 49,000 | 0.0% | 0.01% | -28.6% |
Q4 2017 | $613,000 | +49.5% | 49,000 | 0.0% | 0.01% | +40.0% |
Q3 2017 | $410,000 | -50.7% | 49,000 | 0.0% | 0.01% | -50.0% |
Q2 2017 | $832,000 | -15.5% | 49,000 | 0.0% | 0.01% | -16.7% |
Q1 2017 | $985,000 | +9.0% | 49,000 | -15.5% | 0.01% | 0.0% |
Q4 2016 | $904,000 | +19.4% | 58,000 | 0.0% | 0.01% | +9.1% |
Q3 2016 | $757,000 | – | 58,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 507,191 | $5,107,000 | 0.50% |
Cormorant Asset Management, LP | 356,600 | $3,591,000 | 0.43% |
Perceptive Advisors | 558,446 | $5,623,000 | 0.42% |
NEXTHERA CAPITAL LP | 15,000 | $151,000 | 0.21% |
EMERALD ADVISERS, LLC | 237,070 | $2,387,000 | 0.11% |
AUXIER ASSET MANAGEMENT | 17,857 | $180,000 | 0.04% |
FEDERATED HERMES, INC. | 450,000 | $4,532,000 | 0.01% |
Nationwide Fund Advisors | 49,473 | $498,000 | 0.00% |
Catalyst Capital Advisors LLC | 348 | $4,000 | 0.00% |
DEUTSCHE BANK AG\ | 859 | $8,000 | 0.00% |